From Care Partner to PMHNP: A Personal Journey in Schizophrenia Care

Schizophrenia affects roughly 24 million people worldwide, yet the supply of psychiatrists who treat it remains critically short, particularly in rural and underserved communities. Psychiatric mental health nurse practitioners are filling that gap with increasing clinical autonomy, a defining feature of the evolving role of nurse practitioners, and the best of them bring something no textbook can teach: lived experience as a care partner.

Fines Shaw, DNP, PMHNP, watched her mother receive a schizophrenia diagnosis at age 31 and later saw the same condition emerge in her teenage daughter. Those experiences propelled her from emergency room nursing into psychiatric advanced practice, shaping a clinical lens that balances pharmacologic rigor with genuine empathy. Her perspective, detailed in a July 2026 sponsored post on Daily Nurse, underscores a market reality: as newer agents like COBENFY expand the treatment toolkit, the PMHNPs who combine evidence-based prescribing with patient-centered advocacy will define the next standard of schizophrenia care.

Understanding Schizophrenia and the Expanding PMHNP Role

The psychiatric mental health nurse practitioner workforce has grown rapidly over the past decade, expanding its clinical footprint in one of psychiatry's most complex conditions: schizophrenia.

Schizophrenia: A Multi-Domain Disorder

Under DSM-5-TR criteria, schizophrenia is characterized by the presence of two or more core symptoms persisting for a significant portion of time during a one-month period, with continuous signs of disturbance for at least six months. The symptoms fall into three broad domains:

• Positive symptoms: Hallucinations, delusions, and disorganized speech or behavior that represent experiences added to a person's baseline functioning.
• Negative symptoms: Diminished emotional expression, avolition, alogia, anhedonia, and social withdrawal, which reflect capabilities or drives that are reduced or absent.
• Cognitive symptoms: Deficits in working memory, attention, and executive function that often have the greatest impact on day-to-day functioning and employment.

Diagnosis requires a thorough differential diagnosis to rule out substance use and other medical or psychiatric conditions that could better explain the presentation. Because onset frequently occurs in late adolescence or early adulthood, PMHNPs working across the lifespan encounter patients at every stage of the illness trajectory.

Where PMHNPs Fit in Schizophrenia Management

PMHNPs hold prescriptive authority in all 50 states, though the degree of independence varies.¹ As of 2026, more than half of states plus the District of Columbia grant full practice authority, meaning a PMHNP can independently assess, diagnose, prescribe, and manage treatment without a collaborating physician. In approximately 21 states, independent prescribing is specifically authorized without a collaborative agreement.¹ The remaining states require some level of physician collaboration or supervision, so clinicians should verify their own state nurse practice act.

Beyond prescribing, psychotherapy is a recognized component of PMHNP scope of practice.¹ This means PMHNPs can integrate cognitive behavioral therapy and other evidence-based modalities directly into a schizophrenia treatment plan rather than relying solely on referral. Notably, family nurse practitioners are generally advised to refer patients with severe mental illness like schizophrenia to psychiatric specialists,⁴ reinforcing that schizophrenia management falls squarely within the PMHNP specialties lane.

Guidance From the 2024 APA Practice Guideline

The 2024 APA Practice Guideline for the Treatment of Patients with Schizophrenia offers several core recommendations that directly shape how PMHNPs approach care planning:

• Antipsychotic medication remains the cornerstone of treatment.²
• Ongoing monitoring of medication effectiveness, adverse effects, adherence, and safety is essential.²
• Psychosocial interventions, including family-based approaches, should be integrated alongside pharmacotherapy.³
• Coordinated, multidisciplinary care is recommended to address the full range of patient needs.³

These pillars align well with the PMHNP model of practice, which already emphasizes holistic assessment, therapeutic alliance, and coordination across care settings. For nurse practitioners considering or currently enrolled in a PMHNP program, understanding these guidelines provides a clinical framework that will inform practice from the first patient encounter onward.

From Care Partner to PMHNP: A Journey Fueled by Lived Experience

A care partner is someone who provides ongoing support to a family member or loved one living with a serious illness, often navigating complex healthcare systems while managing the emotional weight of watching someone struggle. For Fines Shaw, DNP, PMHNP, that role shaped not only her personal life but also her entire professional trajectory.

A Family History That Sparked a Calling

Shaw's connection to schizophrenia began long before she entered nursing. Her mother received a schizophrenia diagnosis at age 31, giving Shaw an early window into the challenges families face when mental illness disrupts daily life. Years later, history repeated itself when Shaw's teenage daughter began showing concerning symptoms, including increasing isolation from friends and family activities that once brought her joy.

At the time, Shaw was working as an emergency room nurse, a demanding role that nonetheless left her feeling unprepared for what her daughter was experiencing. When her daughter received her own schizophrenia diagnosis during adolescence, Shaw found herself on the other side of the clinical encounter, advocating for someone she loved while trying to understand a condition that had already touched her family once before.

From the Bedside to Psychiatric Practice

That pivotal moment became the catalyst for Shaw's career change. She pursued advanced education to become a psychiatric and mental health nurse practitioner, driven by the realization that she wanted to help other families navigate what her own had faced. Her lived experience as a care partner gave her something that textbooks alone cannot provide: an intimate understanding of how schizophrenia affects not just the patient but everyone around them.

Lessons That Shape Clinical Practice

Shaw now applies insights from her care partner years directly to her NP practice. She emphasizes listening as a clinical skill, recognizing that patients and families often feel unheard in busy healthcare settings. She advocates for individualized treatment plans because she witnessed firsthand how one-size-fits-all approaches can fail. Her commitment to personalized care stems from knowing what it feels like to sit across from a provider, hoping they truly see your loved one as a whole person rather than a diagnosis code.

Core Pharmacotherapy: Antipsychotics, Long-Acting Injectables, and Relapse Prevention

Which antipsychotic strategy actually keeps adults with schizophrenia out of the hospital, and how should a PMHNP sequence oral versus injectable options in a real practice? The short answer: match the medication to the patient's adherence pattern, insight, and side-effect tolerance, then build a relapse prevention plan around whichever agent you choose.

First- and Second-Generation Agents PMHNPs Prescribe Most

First-generation (typical) antipsychotics like haloperidol and fluphenazine still have a role, particularly in their depot forms, but most PMHNPs reach first for second-generation (atypical) agents because of the more favorable extrapyramidal profile. In everyday practice, the workhorses are risperidone, paliperidone (risperidone's active metabolite), aripiprazole, olanzapine, and increasingly cariprazine and lurasidone. Each carries its own metabolic, sedation, and movement-related trade-offs, and none has been established as a universally superior first-line choice across all patients.

Long-Acting Injectables: Schedules and Evidence

LAIs now span dosing intervals from every two weeks out to every six months³, depending on the product. Paliperidone alone offers monthly (PP1M), 3-month (PP3M), and 6-month (PP6M) formulations, while aripiprazole and risperidone LAIs sit at monthly or bi-monthly intervals. Initiation typically requires oral tolerability testing before the first injection, with overlap dosing for some products.

The evidence base is nuanced. A meta-analysis of 21 randomized controlled trials found no significant difference in relapse between LAIs and orals (RR 0.93)¹, likely because RCT participants are more adherent than real-world patients. Broader 2021 syntheses tell a different story: LAIs reduced hospitalization in RCTs (RR 0.88), cohort studies (RR 0.92), and mirror-image designs (RR 0.44)². A 2025 naturalistic study reported 12-month relapse rates of 8.0% on LAIs versus 31.4% on orals⁴. Head-to-head observational data favor aripiprazole 3-month LAI (aHR 0.77) and paliperidone LAI (aHR 0.66) over their oral counterparts⁵, and PP6M cut relapse by 82% versus PP3M and 89% versus PP1M⁶. Aripiprazole and paliperidone carry moderate-to-high quality evidence; risperidone LAI support is lower⁵.

Oral vs. LAI: A Practical Comparison

• Adherence: Orals rely on daily self-administration; LAIs guarantee dosing between injections and flag missed appointments early.
• Side-effect visibility: Orals can be stopped immediately if intolerable; LAIs persist for weeks, so oral tolerability testing matters.
• Patient selection: Consider LAIs for patients with prior nonadherence, frequent relapse, limited insight, unstable housing, or those who simply prefer not to think about pills daily.
• Access and cost: LAIs require clinic infrastructure and insurance navigation that orals do not.

Relapse Prevention Planning

Every prescription should be paired with a written relapse prevention plan. Map each patient's individual early warning signs (sleep disruption, social withdrawal, suspiciousness, hearing familiar voices returning), name the people who can call the office, and set follow-up cadence tighter than you think you need in the first 90 days. Missed LAI appointments should trigger same-week outreach, not a wait-and-see approach, because catching a lapse at week one is very different from catching it at week six.

Does NP-Led Care Improve Schizophrenia Outcomes?

The push to expand PMHNP independent practice often collides with a simple question: do patients with schizophrenia fare as well under NP-led care as they do under psychiatrists? The honest answer is that direct comparative evidence is thin, but what exists leans favorably toward NPs while revealing a research gap that needs filling.

What the evidence says (and doesn't say) about PMHNP outcomes

A 2023 systematic review of 17 studies on NP mental health care found that in four high-quality studies, NP prescribing and evidence-based practice were comparable to physicians.¹ Seven lower-quality studies suggested NP-led collaborative care reduced symptoms, primarily for depression, anxiety, and substance use. However, no included study specifically isolated schizophrenia outcomes like hospitalization rates or long-term symptom control for PMHNP-managed patients versus psychiatrists. A separate 2023 review of NP outcomes noted that one NP-led transitional care study increased primary care visits but did not significantly change emergency department visits or hospitalizations, though it was not specific to schizophrenia.²

A 2024 study on refined nursing care for schizophrenia reported meaningful gains in symptom management, medication adherence, and quality of life compared with standard care, but the intervention involved nursing teams broadly, not a direct NP-versus-physician comparison.³ So while these studies confirm that nursing-driven interventions improve outcomes, they don't directly answer the head-to-head question.

The real-world impact in underserved settings

Even without a randomized comparison, PMHNPs are demonstrably moving the needle where it matters most. In rural communities, community health centers, and correctional facilities with severe psychiatrist shortages, PMHNPs often act as the sole prescribers of antipsychotic therapy. For patients in these settings, the alternative to NP-led care is often no care at all, meaning delayed diagnosis, untreated psychosis, and avoidable hospitalizations. Anecdotal and workforce data consistently show that when PMHNPs step into these gaps, time-to-treatment shortens and continuity of care improves, both of which are linked to better schizophrenia outcomes in the broader literature.

Why this evidence matters for NP advocacy

The absence of negative comparative data is itself a meaningful signal. If PMHNP-led schizophrenia care were producing worse outcomes, the disparities would likely have surfaced in the large-scale utilization patterns now tracked by payers and health systems. The existing evidence of comparable quality in general mental health care, combined with NPs' critical role in expanding access, strengthens the case for nurse practitioner advocacy and lifting nurse practitioner scope of practice barriers. For PMHNPs, the next step is pushing for rigorous, schizophrenia-specific outcome studies, hospitalization rates, medication adherence, functional recovery, that can turn plausible benefit into hard data. Until then, the current evidence base, while incomplete, supports the value of NP-led care and the wisdom of letting PMHNPs practice to the full extent of their training.

Spotlight on COBENFY: A Novel Antipsychotic Without Dopamine D2 Binding

COBENFY is a twice-daily oral medication for adults with schizophrenia that works through an entirely different pathway than traditional antipsychotics. Instead of blocking dopamine D2 receptors, it combines two active ingredients, xanomeline and trospium chloride, to target the muscarinic receptor system. For nurse practitioners managing patients who struggle with the metabolic or neurological side effects of conventional antipsychotics, understanding how this medication works and who it may benefit is increasingly relevant to clinical practice.

How the Mechanism Differs From Traditional Antipsychotics

Xanomeline is a muscarinic receptor agonist that preferentially activates M1 and M4 receptors. By stimulating these receptors, it is believed to modulate dopamine release indirectly rather than blocking it at the D2 receptor.¹ The exact mechanism is not fully understood, but this upstream approach avoids the receptor blockade responsible for many familiar antipsychotic side effects.

Trospium chloride, the second ingredient, is a peripherally acting muscarinic antagonist. Its role is to counteract the cholinergic side effects (such as excessive salivation and gastrointestinal distress) that xanomeline alone would cause in the rest of the body. Together, the combination lets the central nervous system benefit from muscarinic activation while limiting peripheral discomfort.

What the EMERGENT Trials Showed

COBENFY's evidence base comes from the EMERGENT clinical trial program, which includes three short-term, five-week, randomized, double-blind, placebo-controlled studies and long-term extension data encompassing more than 1,250 patients.

• EMERGENT-2: Patients taking COBENFY experienced a 9.6-point greater reduction in total symptom scores compared to placebo at week five.¹ A secondary measure of overall clinical severity also showed statistically significant improvement.
• EMERGENT-3: This trial demonstrated an 8.4-point greater reduction in total symptom scores versus placebo at week five. Notably, however, the benefit on the negative symptom subscale was not statistically significant¹, so NPs should understand that negative symptom improvement has not been consistent across all pivotal trials.
• Long-term data: Over 52 weeks, improvements were maintained or continued. Among patients who completed the extension period, roughly 69 percent achieved at least a 30 percent improvement from baseline², with no new safety signals emerging over that time frame.

Efficacy appeared as early as two weeks into treatment and persisted through five weeks and beyond, a timeline that aligns well with patient and family expectations if you set them early.¹

Side-Effect Profile: What NPs Should Watch For

Because COBENFY does not block D2 receptors, the side effects that often drive patients away from traditional antipsychotics were notably absent in clinical trials. No significant extrapyramidal symptoms, prolactin elevations, or metabolic changes were observed.¹ For patients who have gained weight, developed akathisia, or experienced hormonal disruption on prior medications, this profile is worth noting.

The most common adverse effects were gastrointestinal and cholinergic in nature:

• Nausea (9.2 percent)
• Dyspepsia (8.6 percent)
• Vomiting (8.6 percent)
• Dry mouth (5.3 percent)
• Hypertension (5.3 percent)¹

About 10.5 percent of patients in the trials discontinued treatment because of adverse events.¹ Blood pressure monitoring and early management of nausea are practical steps NPs can build into follow-up protocols.

Guidance on Patient Selection

PMHNPs should consider COBENFY as a potential option for adult patients with schizophrenia who meet certain criteria:

• Patients with metabolic syndrome risk factors or those who have experienced clinically significant weight gain on D2-blocking antipsychotics.
• Patients who have developed extrapyramidal symptoms or tardive dyskinesia and need an alternative mechanism.
• Adults who have not responded adequately to conventional antipsychotic therapy.

At the same time, candidates should be able to tolerate potential gastrointestinal effects and adhere to blood pressure monitoring. Because the negative symptom benefit was inconsistent across the pivotal trials, NPs should set realistic expectations when negative symptoms are the primary treatment target. For a deeper look at the trial data, resources from Bristol Myers Squibb, a Lancet publication on xanomeline-trospium, and published reviews in the NIH literature provide additional clinical detail.

As Fines Shaw, DNP, PMHNP, has noted from both personal and clinical experience, expanding the range of available treatment options matters enormously when the goal is individualized, patient-centered care. COBENFY represents a meaningful addition to the PMHNP toolkit, provided prescribers apply it with the careful candidate selection that any newer therapy demands.

Related Articles

Schizophrenia care is shifting toward a both-and model rather than an either-or debate: lived empathy and evidence-based pharmacology now work together in the PMHNP toolkit. Fines Shaw's path from care partner to prescriber is a reminder that clinical authority grows stronger when paired with genuine understanding of what patients and families endure. At the same time, tools like long-acting injectables and novel options such as COBENFY, with its non-dopamine D2 mechanism, offer nurse practitioners more ways to individualize treatment.

For practicing NPs, the takeaway is straightforward: listen closely, involve families, stay current on emerging antipsychotics, and build relapse-prevention plans around each patient's actual life, not a generic protocol. When you champion that holistic standard, outcomes follow.